This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
by Zacks Equity Research
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
Prothena's Psoriasis Candidate Disappoints in Phase I Study
by Zacks Equity Research
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
by Zacks Equity Research
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Kite Pharma Triples So Far in 2017: What's Driving the Rally?
by Zacks Equity Research
Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.
Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq
by Zacks Equity Research
Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
by Zacks Equity Research
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
by Arpita Dutt
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.
How is the Age-Related Macular Degeneration Space Faring Now?
by Zacks Equity Research
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
Mylan Down 24% Year to Date: What's Troubling the Stock?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.
Novartis Poised to Grow on Oncology Portfolio & Biosimilars
by Zacks Equity Research
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.
Roche (RHHBY) Announces Positive Data on Leukemia Drug
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
Novartis Announces Positive Data on Urticaria Drug Xolair
by Zacks Equity Research
Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
Oncology Space in Focus this Week on ESMO Presentations
by Zacks Equity Research
There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
by Zacks Equity Research
The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).
Roche (RHHBY) Announces Data on Respiratory Drug Esbriet
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
by Zacks Equity Research
Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.
Array's NDAs for Melanoma Combo Accepted for Review by FDA
by Zacks Equity Research
Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.
Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
by Zacks Equity Research
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.